Exelon Patch FAQ
Links shared publicly online about this topic
Novartis files suit against Watson over generic Exelon
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr.” View full resource at news-medical.net
Most Recently Shared on November 11, 2011 at 5:17 am By:
Parkinson's Disease: Novartis files suit against Watson over generic Exelon: Watson Pharmaceuticals, Inc. today ... http://t.co/ldd6pUdi
Updated NICE Guidance For Alzheimer's Disease Now Recommends The First Transdermal Patch As Well As Oral Capsules
medicalnewstoday.com — “Novartis Pharmaceuticals UK Ltd. welcomes the update to National Institute for Health and Clinical Excellence (NICE) guidance TA1111 and is pleased that the EXELON Patch (rivastigmine transdermal” View full resource at medicalnewstoday.com
Most Recently Shared on January 19, 2011 at 1:05 pm By:
MNT Alzheimer's News Health News
Updated NICE Guidance For Alzheimer's Disease Now Recommends The First Transdermal Patch As Well As Oral Capsules http://mnt.to/3Q69
Lower Dementia Drug Dose Boosts Brain Function, Cuts Side Effects
sciencedaily.com — “Sometimes less is more: Lower doses of an Alzheimer's drug delivered via skin patches improve cognition with fewer serious side effects than higher doses, researchers have found in an updated review.” View full resource at sciencedaily.com
Most Recently Shared on April 29, 2009 at 2:42 pm By:
William Yates, M.D. Family Medicine Doctor, Physician, Doctor, and Psychiatrist
Exelon low-dose patch effective with less side effects in Alzheimer's. Cochrane Review http://bit.ly/FlxXS
FAQ: The 'Doc Fix' Dilemma - Kaiser Health News
kaiserhealthnews.org — “FAQ: The 'Doc Fix' Dilemma - Kaiser Health News” View full resource at kaiserhealthnews.org
Most Recently Shared on December 15, 2011 at 6:28 pm By:
Kaiser Health News Health News
FAQ: The 'Doc Fix' Dilemma (A primer on the fight) http://t.co/2IHfixaM
Drug Therapies for Cognitive Impairment and Dementia
jpnonline.com — “ABSTRACT Drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease include acetylcholinesterase inhibitor drugs (tacrine [Cognex], donepezil [A” View full resource at jpnonline.com
Most Recently Shared on April 25, 2010 at 8:25 am By:
Drug Therapies for Cognitive Impairment and Dementia http://ow.ly/1Adzj
Nuclear Builders Keep Their Options Open - NYTimes.com
green.blogs.nytimes.com — “Nuclear companies may not be certain they want to build, but they are doing the groundwork anyway.” View full resource at green.blogs.nytimes.com
Most Recently Shared on December 27, 2010 at 11:12 pm By:
NYTimes Science Science Enthusiast
Green: Nuclear Builders Keep Their Options Open http://bit.ly/hVob4V
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest Parkinson's Disease news and research via News-Medical.Net
-
MNT Alzheimer's News
The latest Alzheimer's and Dementia news published daily. Articles from research centers, universities and prestigious journals.
-
William Yates, M.D.
Clinical Neuroscientist. Research Psychiatrist, Laureate Institute of Brain Research (laureateinstitute.org) Professor of Research, University of Oklahoma.
Advertisement
